Biography and Research Information
OverviewAI-generated summary
Aaron Johnson's research focuses on the therapeutic potential of vaccines, particularly in the context of cancer recurrence. His work includes a Phase I/II clinical trial investigating the efficacy of a human papillomavirus (HPV) therapeutic vaccine, PepCan, designed to reduce the recurrence of head and neck cancers. This trial is randomized, double-blind, and placebo-controlled, employing rigorous methodology to assess the vaccine's impact. Johnson collaborates with researchers at the University of Arkansas for Medical Sciences, including David W. Ussery, Jennifer L. Faulkner, Yong‐Chen Lu, and Jumin Sunde, on shared publications. His scholarly output includes one publication, with recent activity indicated.
Metrics
- Publications: 1
Selected Publications
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
Collaboration Network
Top Collaborators
Emily Ward Bivens
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Omar Atiq
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Teresa Evans
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Milan Bilami
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Ginger Brown
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jasmine Crane
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Rangaswamy Govindarajan
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Alongkorn Kurilung
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Oxana P. Lazarenko
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Yong-Chen William Lu
University of Arkansas for Medical Sciences (US)
1 shared publication
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Keanna Marsh
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
M Moreno
University of Arkansas for Medical Sciences (US)
1 shared publication
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Similar Researchers
Based on overlapping research topics
Milan Bilami
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Mindy Wilman
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Yong-Chen William Lu
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Emre Duval
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Teresa Evans
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Keanna Marsh
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy